Compare Eli Lilly And Co (LLY) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Koninklijke Philips NV — how do they compare? Eli Lilly And Co trades at $1,215.82 (market cap $1.08T), while Koninklijke Philips NV trades at $26.81 (market cap $26.58B). The key difference: Eli Lilly And Co is far larger — about 40.6× Koninklijke Philips NV's market cap, and Koninklijke Philips NV pays the higher dividend (3.75%). Which is the better fit depends on your goals.
| LLY | PHG | |
|---|---|---|
Market Cap | $1.08T | $26.58B |
Sector | Health | Health |
52-Week High | $1.24K | $32.91 |
52-Week Low | $639.43 | $25.02 |
Enterprise Value | $1.13T | $33.13B |
Dividend Yield | 0.57% | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
PHG trades at $26.77, down 0.63% on the day, with a bullish technical signal supported by moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and a return to profitability in 2025 after previous losses. Recent news highlights Exor's potential stake increase to 22% and FDA clearances for new medical devices, supporting positive sentiment.
The outlook remains constructive with 41% analyst buy ratings and no sell recommendations, though near-term risks include order timing volatility and China market weakness. Earnings momentum and institutional accumulation provide support, while valuation appears reasonable at P/E 20.53 and P/S 1.28 relative to sector peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
